JANX · Janux Therapeutics, Inc.
Market Cap
$1.05B
Shares
61.14M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$17.10
Open$17.92
Day$17.05–17.94
52W close$12.18–34.74
Avg vol 30d788K
Short int6.1M · 9.9% float · 7.8d
Short vol67%
Last earningsDec 1, 2025
DataJun 2021–Sep 2026
Filing10-Q · Aug 6
Up next
filed Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$24.00M
Trailing 12 months
Net income (TTM)
−$102.59M
Trailing 12 months
Revenue growth YoY
-5.6%
Year over year
Operating margin
-598.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-3.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$970.91M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.7%
Year over year · more shares
Price change (1Y)
-27.3%
Trailing year
Short interest
9.9%
Latest settlement · 7.8 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.60
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+11%
above
Price vs 50-day avg
+1%
above
RSI (14)
44
neutral
MACD trend
Negative
52-week position
22%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+7%
trailing
6-month return
+22%
trailing
YTD return
+24%
this year
Relative strength
+4%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $17 › 200d $15 — 50d above 200d
Institutional flow
Accumulating
+4% holders QoQ · +40 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
9.92% of float · ▼ -8.5% MoM · 7.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
199 holders — mid 3-yr range
Squeeze score
69
elevated · 0–100
Fundamentals
Revenue growth
−6%
Y/Y
EPS growth
−43%
Y/Y
Free cash flow
$-83.3M
Quant / Vol
risk profile
Volatility
74%
annualized · 1-yr
Max drawdown
−65%
past year
ATR
4.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+11%
Bullish
Price vs 50-day avg
+1%
Bullish
RSI (14)
44
Neutral
MACD trend
Negative
Bearish
52-week position
22%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $17 › 200d $15 — 50d above 200d
Institutional flow
Accumulating
+4% holders QoQ · +40 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
9.92% of float · ▼ -8.5% MoM · 7.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
199 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $12
Now $17 · 22%
Range high $35
vs 200-day avg +11%
vs 50-day avg +1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
JANX
this stock
Janux Therapeutics, Inc.
|
$1.05B | +23.9% | -5.6% | — | 9.9% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.40B | +13.7% | +46.2% | 30.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.46B | +1.2% | +20.8% | 19.4 | 2.5% |
|
ARGX
Argenx SE
|
$61.60B | +17.1% | — | — | 2.0% |
|
MRNA
Moderna, Inc.
|
$57.48B | +388.2% | +4.3% | — | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| JANX | -13.6% | +6.9% | +21.6% | -6.2% | +23.9% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -12.5% | +8.6% | +3.8% | -5.8% | +11.8% |